Effects of stuffer DNA on transgene expression from helper-dependent adenovirus vectors

Journal of Virology

Volumn 73, Issue 10, 1999, Pages 8027-8034

  Parks, Robin J ^a,b   Bramson, Jonathan L ^a   Wan, Yonghong ^a   Addison, Christina L ^a,c   Graham, Frank L ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; VIRUS DNA; VIRUS VECTOR;

ADENOVIRUS; ANIMAL TISSUE; ARTICLE; CYTOTOXIC T LYMPHOCYTE; FEMALE; GENE CASSETTE; GENE DELETION; GENE EXPRESSION; GENETIC CODE; GENETIC TRANSDUCTION; HELPER VIRUS; KINETICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENE;

EID: 0032850174     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.73.10.8027-8034.1999     Document Type: Article

References (67)

1. Addison, C. L., M. Hitt, D. Kunsken, and F. L. Graham. 1997. Comparison of the human versus murine cytomegalovirus immediate early gene promoters for transgene expression by adenoviral vectors. J. Gen. Virol. 78:1653-1661.
2. Agarwal, M., T. W. Austin, F. Morel, J. Chen, E. Bohnlein, and I. Plavec. 1998. Scaffold attachment region-mediated enhancement of retroviral vector expression in primary T cells. J. Virol. 72:3729-3728.
3. Armentano, D., C. C. Sookdeo, K. M. Hehir, R. J. Gregory, St, G. A. Prince, S. C. Wadsworth, and A. E. Smith. 1995. Characterization of an adenovirus gene transfer vector containing an E4 deletion. Hum. Gene Ther. 6:1343-1353.
4. Besse, S., and F. Puvion-Dutilleul. 1994. Compartmentalization of cellular and viral DNAs in adenovirus type 5 infection as revealed by ultrastructural in situ hybridization. Chromosome Res. 2:123-135.
5. Bett, A. J., L. Prevec, and F. L. Graham. 1993. Packaging capacity and stability of human adenovirus type 5 vectors. J. Virol. 67:5911-5921.
6. Bramson, J. L., F. L. Graham, and J. Gauldie. 1995. The use of adenoviral vectors for gene therapy and gene transfer in vivo. Curr. Opin. Biotechnol. 6:590-595.
7. Chen, H. H., L. M. Mack, R. Kelly, M. Ontell, S. Kochanek, and P. R. Clemens. 1997. Persistence in muscle of an adenoviral vector that lacks all viral genes. Proc. Natl. Acad. Sci. USA 94:1645-1650.
8. Chen, L., M. Anton, and F. L. Graham. 1996. Production and characterization of human 293 cell lines expressing the site-specific recombinase Cre. Somat. Cell. Mol. Genet. 22:477-488.
9. Clemens, P. R., S. Kochanek, Y. Sunada, S. Chan, H. H. Chen, K. P. Campbell, and C. T. Caskey. 1996. In vivo muscle gene transfer of full-length dystrophin with an adenoviral vector that lacks all viral genes. Gene Ther. 3:965-972.
10. Cowdery, J. S., J. H. Chace, A. K. Yi, and A. M. Krieg. 1996. Bacterial DNA induces NK cells to produce IFN-gamma in vivo and increases the toxicity of lipopolysaccharides. J. Immunol. 156:4570-4575.
11. Dai, Y., E. M. Schwarz, D. Gu, W. W. Zhang, N. Sarvetnick, and I. M. Verma. 1995. Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression. Proc. Natl. Acad. Sci. USA 92:1401-1405.
12. Davis, H. L., R. Weeranta, T. J. Waldschmidt, L. Tygrett, J. Schorr, and A. M. Krieg. 1998. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J. Immunol. 160:870-876.
13. Dedieu, J. F., E. Vigne, C. Torrent, C. Jullien, I. Mahfouz, J. M. Caillaud, N. Aubailly, C. Orsini, J. M. Guillaume, P. Opolon, P. Delaere, M. Perricaudet, and P. Yeh. 1997. Long-term gene delivery into the livers of immunocompetent mice with E1/E4-defective adenoviruses. J. Virol. 71:4626-4637.
14. Engelhardt, J. F., X. Ye, B. Doranz, and J. M. Wilson. 1994. Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. Proc. Natl. Acad. Sci. USA 91:6196-6200.
15. Fang, B., H. Wang, G. Gordon, D. A. Bellinger, M. S. Read, K. M. Brinkhous, S. L. Woo, and R. C. Eisensmith. 1996. Lack of persistence of El-recombinant adenoviral vectors containing a temperature-sensitive E2A mutation in immunocompetent mice and hemophilia B dogs. Gene Ther. 3:217-222.
16. Fisher, K. J., H. Choi, J. Burda, S. J. Chen, and J. M. Wilson. 1996. Recombinant adenovirus deleted of all viral genes for gene therapy of cystic fibrosis. Virology 217:11-22.
17. Gao, G. P., Y. Yang, and J. M. Wilson. 1996. Biology of adenovirus vectors with E1 and E4 deletions for liver-directed gene therapy. J. Virol. 70:8934-8943.
18. Goldhamer, D. J., B. P. Brunk, A. Faerman, A. King, M. Shani, and C. P. Emerson, Jr. 1995. Embryonic activation of the myoD gene is regulated by a highly conserved distal control element. Development 121:637-649.
19. Goldhamer, D. J., A. Faerman, M. Shani, and C. P. Emerson, Jr. 1992. Regulatory elements that control the lineage-specific expression of myoD. Science 256:538-542.
20. Goldman, M. J., L. A. Litzky, J. F. Engelhardt, and J. M. Wilson. 1995. Transfer of the CFTR gene to the lung of nonhuman primates with E1-deleted, E2a-defective recombinant adenoviruses: a preclinical toxicology study. Hum. Gene Ther. 6:839-851.
21. Gorziglia, M. I., M. J. Kadan, S. Yei, J. Lim, G. M. Lee, R. Luthra, and B. C. Trapnell. 1996. Elimination of both E1 and E2 from adenovirus vectors further improves prospects for in vivo human gene therapy. J. Virol. 70: 4173-4178.
22. Graham, F. L. 1984. Covalently closed circles of human adenovirus DNA are infectious. EMBO J. 3:2917-2922.
23. Graham, F. L., J. Smiley, W. C. Russell, and R. Nairn. 1977. Characteristic of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol. 36:59-74.
24. Guidotti, L. G., P. Borrow, A. Brown, H. McClary, R. Koch, and F. V. Chisari. 1999. Noncytopathic clearance of lymphocytic choriomeningitis virus from the hepatocyte. J. Exp. Med. 189:1555-1564.
25. Guidotti, L. G., R. Rochford, J. Chung, M. Shapiro, R. Purcell, and F. V. Chisari. 1999. Viral clearance without destruction of infected cells during acute HBV infection. Science 284:825-829.
26. Haecker, S. E., H. H. Stedman, R. J. Bailee-Gordon, D. B. Smith, J. P. Greelish, M. A. Mitchell, A. Wells, H. L. Sweeney, and J. M. Wilson. 1996. In vivo expression of full-length human dystrophin from adenoviral vectors deleted of all viral genes. Hum. Gene Ther. 7:1907-1914.
27. Hardy, S., M. Kitamura, T. Harris-Stansil, Y. Dai, and M. L. Phipps. 1997. Construction of adenovirus vectors through Cre-lox recombination. J. Virol. 71:1842-1849.
28. Hitt, M., A. J. Bett, C. L. Addison, L. Prevec, and F. L. Graham. 1995. Techniques for human adenovirus vector construction and characterization. Methods Mol. Genet. 7:13-30.
29. Hitt, M. M., C. L. Addison, and F. L. Graham. 1997. Human adenovirus vectors for gene transfer into mammalian cells. Adv. Pharmacol. 40:137-206.
30. Jooss, K., Y. Yang, and J. M. Wilson. 1996. Cyclophosphamide diminishes inflammation and prolongs transgene expression following delivery of adenoviral vectors to mouse liver and lung. Hum. Gene Ther. 7:1555-1566.
31. Kafri. T., D. Morgan, T. Krahl, N. Sarvetnick, L. Sherman, and I. Verma. 1998. Cellular immune response to adenoviral vector infected cells does not require de novo viral gene expression: implications for gene therapy. Proc. Natl. Acad. Sci. USA 95:11377-11382.
32. Kass-Eisler, A., L. Leinwand, J. Gall, B. Bloom, and E. Falck-Pedersen. 1996. Circumventing the immune response to adenovirus-mediated gene therapy. Gene Ther. 3:154-162.
33. Kochanek, S., P. R. Clemens, K. Mitani, H. H. Chen, S. Chan, and C. T. Caskey. 1996. A new adenoviral vector: replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and beta-galactosidase. Proc. Natl. Acad. Sci. USA 93:5731-5736.
34. Kolls, J. K., D. Lei, G. Odom, S. Nelson, W. R. Summer, M. A. Gerber, and J. E. Shellito. 1996. Use of transient CD4 lymphocyte depletion to prolong transgene expression of E1-deleted adenoviral vectors. Hum. Gene Ther. 7:489-497.
35. Krieg, A. M., T. Wu, R. Weeratna, S. M. Efler, L. Love-Homan, L. Yang, A. K. Yi, D. Short, and H. L. Davis. 1998. Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs. Proc. Natl. Acad. Sci. USA 95:12531-12636.
36. Krieg, A. M., A. K. Yi, S. Matson, T. J. Waldschmidt, G. A. Bishop, R. Teasdale, G. A, Koretzky, and D. M. Klinman. 1995. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374:546-549.
37. Kumar-Singh, R., and J. S. Chamberlain. 1996. Encapsidated adenovirus minichromosomes allow delivery and expression of a 14 kb dystrophin cDNA to muscle cells. Hum. Mol. Genet. 5:913-921.
38. Kuzmin, A. I., M. J. Finegold, and R. C. Eisensmith. 1997. Macrophage depletion increases the safety, efficacy and persistence of adenovirus-mediated gene transfer in vivo. Gene Ther. 4:309-316.
39. Lieber, A, C. Y. He, I. Kiroillova, and M. A. Kay. 1996. Recombinant adenoviruses with large deletions generated by Cre-mediated excision exhibit different biological properties compared with first-generation vectors in vitro and in vivo. J. Virol. 70:8944-8960.
40. Lochmuller, H., B. J. Petrof, G. Pari, N. Larochelle, V. Dodelet, Q. Wang, C. Allen, S. Prescott, B. Massie, J. Nalbantoglu, and G. Karpati. 1996. Transient immunosuppression by FK506 permits a sustained high-level dystrophin expression after adenovirus-mediated dystrophin minigene transfer to skeletal muscles of adult dystrophic (mdx) mice. Gene Ther. 3:706-716.
41. Lusky, M., M. Christ, K. Rittner, A. Dieterle, D. Dreyer, B. Mourot, H. Schultz, F. Stoeckel, A. Pavirani, and M. Mehtali. 1998. In vitro and in vivo biology of recombinant adenovirus vectors with E1, E1/E2A, or E1/E4 deleted. J. Virol. 72:2022-2032.
42. Michou, A. I., L. Santoro, M. Christ, V. Julliard, A. Pavlrani, and M. Mehtali. 1997. Adenovirus-mediated gene transfer: influence of transgene, mouse strain and type of immune response on persistence of transgene expression. Gene Ther. 4:473-482.
43. Miller, J. 1972. Experiments in molecular genetics. Cold Spring Harbor Laboratories, Cold Spring Harbor, N.Y.
44. Mitani, K., F. L. Graham, C. T. Caskey, and S. Kochanek. 1995. Rescue, propagation, and partial purification of a helper virus-dependent adenovirus vector. Proc. Natl. Acad, Sci. USA 92:3854-3858.
45. Morral, N., W. O'Neal, H. Zhou, C. Langston, and A. Beaudet. 1997. Immune responses to reporter proteins and high viral dose limit duration of expression with adenoviral vectors: comparison of E2a wild type and E2a deleted vectors. Hum. Gene Ther. 8:1275-1286.
46. Morral, N., R. J. Parks, H. Zhou, C. Langston, G. Schiedner, J. Quinones, F. L. Graham, S. Kochanek, and A. L. Beaudet. 1998. High doses of a helper-dependent adenoviral vector yield supraphysiological levels of alpha 1-antitrypsin with negligible toxicity. Hum. Gene Ther. 9:2709-2716.
47. Morsy, M. A., M. Gu, S. Motzel, J. Zhao, J. Lin, Q. Su, H. Allen, L. Franlin, R. J. Parks, F. L. Graham, S. Kochanek, A. J. Bett, and C. T. Caskey. 1998. An adenoviral vector deleted for all viral coding sequences results in enhanced safety and extended expression of a leptin transgene. Proc. Natl. Acad. Sci. USA 95:7866-7871.
48. Parks, R. J., L. Chen, M. Anton, U. Sankar, M. A. Rudnicki, and F. L. Graham. 1996. A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal. Proc. Natl. Acad. Sci. USA 93:13565-13570.
49. Parks, R. J., C. M. Evelegh, and F. L. Graham. Use of helper-dependent adenoviral vectors of alternative serotype permits repeat vector administration. Gene Ther., in press.
50. Parks, R. J., and F. L. Graham. 1997. A helper-dependent system for adenovirus vector production helps define a lower limit for efficient DNA packaging. J. Virol. 71:3293-3298.
51. Sawchuk, S. J., G. P. Boivin, L. E. Duwel, W. Ball, K. Bove, B. Trapnell, and R. Hirsch. 1996. Anti-T cell receptor monoclonal antibody prolongs transgene expression following adenovirus-mediated in vivo gene transfer to mouse synovium. Hum. Gene Ther. 7:499-506.
52. Schaack, J., W. Y. Ho, P. Freimuth, and T. Shenk. 1990. Adenovirus terminal protein mediates both nuclear matrix association and efficient transcription of adenovirus DNA. Genes Dev. 4:1197-1208.
53. Schiedner, G., N. Morral, R. J. Parks, Y. Wu, S. C. Koopmans, C. Langston, F. L. Graham, A. L. Beaudet, and S. Kochanek. 1998. Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity. Nat. Genet. 18:180-183.
54. Stacey, K. J., M. J. Sweet, and D. A. Hume. 1996. Macrophages ingest and are activated by bacterial DNA. J. Immunol. 157:2116-2122.
55. Sykes, R. C, D. Lin, S. J. Hwang, P. E. Framson, and A. C. Chinault. 1988. Yeast ARS function and nuclear matrix association coincide in a short sequence from the human HPRT locus. Mol. Gen. Genet. 212:301-309.
56. Tripathy, S. K., H. B. Black, E. Goldwasser, and J. M. Leiden. 1996. Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors. Nat. Med. 2:545-550.
57. Vilquin, J. T., B. Guerette, I. Kinoshita, B. Roy, M. Goulet, C. Gravel, R. Roy, and J. P. Tremblay. 1995. FK506 immunosuppression to control the immune reactions triggered by first-generation adenovirus-mediated gene transfer. Hum. Gene Ther. 6:1391-1401.
58. Wadsworth, S. C., H. Zhou, A. E. Smith, and J. M. Kaplan. 1997. Adenovirus vector-infected cells can escape adenovirus antigen-specific cytotoxic T-lymphocyte killing in vivo. J. Virol. 71:5189-5196.
59. Wan, Y., J. Bramson, R. Carter, F. Graham, and J. Gauldie. 1997. Dendritic cells transduced with an adenoviral vector encoding a model tumor-associated antigen for tumor vaccination. Hum. Gene Ther. 8:1355-1363.
60. Wolff, G., S. Worgall, R. N. van, W. R. Song, B. G. Harvey, and R. G. Crystal. 1997. Enhancement of in vivo adenovirus-mediated gene transfer and expression by prior depletion of tissue macrophages in the target organ. J. Virol. 71:624-629.
61. Worgall, S., G. Wolff, E. Falck-Pedersen, and R. G. Crystal. 1997. Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration. Hum. Gene Ther. 8:37-44.
62. Yang, Y., K. Greenough, and J. M. Wilson. 1996. Transient immune blockade prevents formation of neutralizing antibody to recombinant adenovirus and allows repeated gene transfer to mouse liver. Gene Ther. 3:412-420.
63. Yang, Y., Q. Li, H. C. Ertl, and J. M. Wilson. 1995. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J. Virol. 69:2004-2015.
64. Yang, Y., F. A. Nunes, K. Berencsi, E. E. Furth, E. Gonczol, and J. M. Wilson. 1994. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc. Natl. Acad. Sci. USA 91:4407-4411.
65. Yang, Y., F. A. Nunes, K. Berencsi, E. Gonczol, J. F. Engelhardt, and J. M. Wilson. 1994. Inactivation of E2a in recombinant adenoviruses improves the prospect for gene therapy in cystic fibrosis. Nat. Genet. 7:362-369.
66. Yang, Y., Z. Xiang, H. C. Ertl, and J. M. Wilson. 1995. Upregulation of class I major histocompatibility complex antigens by Interferon gamma is necessary for T-cell-mediated elimination of recombinant adenovirus-infected hepatocytes in vivo. Proc. Natl. Acad. Sci. USA 92:7257-7261.
67. Zepeda, M., and J. M. Wilson. 1996. Neonatal cotton rats do not exhibit destructive immune responses to adenoviral vectors. Gene Ther. 3:973-979.